.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,201,556

« Back to Dashboard
Patent 8,201,556 protects ARNUITY ELLIPTA and INCRUSE ELLIPTA and is included in two NDAs.

This patent has thirteen patent family members in thirteen countries.

Summary for Patent: 8,201,556

Title:Medicament dispenser
Abstract: There is provided a sheet driver for use in a medicament dispenser including a medicament carrier having a plurality of pockets for containing medicament wherein said pockets are spaced along the length of and defined between first and second sheets secured to each other and separable by drivable pulling action, the sheet driver comprising a base; ascending from the base, a shaft defining a rotational axis; on the base, a drive surface for receipt of drive to rotate the base about the rotational axis; about the shaft, a torsion spring defining first and second spring legs; mounting about the shaft and the torsion spring for rotation about the rotational axis, a hub defining a hub surface for receipt of a sheet of the medicament carrier. A first leg receiver of the base receives the first spring leg of the torsion spring and a second leg receiver of the hub receives the second spring leg of the torsion spring such that relative rotation of the base and the hub results in tensioning of the torsion spring.
Inventor(s): Jones; Christopher John (Warwick, GB), May; James John (Warwick, GB), Lintell; Daniel Thomas De Sausmarez (Ware, GB), Palmer; Mark Gregory (Ware, GB), Tansley; Robert William (Bidford on Avon, GB)
Assignee: Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:11/573,656
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Medical technology
Back Citations: 90th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxosmithkline
ARNUITY ELLIPTA
fluticasone furoate
POWDER;INHALATION205625-001Aug 20, 2014RXYes8,201,556► subscribeY
Glaxosmithkline
ARNUITY ELLIPTA
fluticasone furoate
POWDER;INHALATION205625-002Aug 20, 2014RXYes8,201,556► subscribeY
Glaxo Grp England
INCRUSE ELLIPTA
umeclidinium bromide
POWDER;INHALATION205382-001Apr 30, 2014RXYes8,201,556► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,201,556

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0418278.8Aug 16, 2004
PCT Information
PCT FiledAugust 12, 2005PCT Application Number:PCT/EP2005/008842
PCT Publication Date:February 23, 2006PCT Publication Number: WO2006/018261

Non-Orange Book Patents for Patent: 8,201,556

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,333,310Medicament dispenser► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,201,556

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1786498► subscribe
Mexico2007001956► subscribe
Japan4960868► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc